Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Inclusion Criteria:

* Written informed consent provided.
* Males or females aged ≥18 years, \< 75 years.
* Target population is completely resected pathological stage IIIA-N2 NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.
* Underwent radical resection
* The patient did not receive any neoadjuvant chemotherapy or EGFR-TKI targeted therapy before surgery
* Patient who can start the investigational therapy within 3-6 weeks after the complete resection
* ECOG performance status 0-1.
* Life expectancy ≥12 weeks.
* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.
* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.
* Female subjects should not be pregnant or breast-feeding.

Exclusion Criteria:

* Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
* Patients with prior any systemic chemotherapy, immunotherapy or biotherapy
* Known severe hypersensitivity to gefitinib or any of the excipients of this product.
* Patients with prior radiotherapy.
* Not fully recovered from the previous surgery.
* History of another malignancy in the last 5 years with the exception of the following: basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix.
* Patients who harbouring exon 20 T790M mutation.
* Patient who has any active infection (e.g. acute pneumonia, hepatitis B or hepatitis C).
* Dysphagia or known malabsorption of drugs.
* Patient with serious heart, liver, kidney or other important organ dysfunction.
* Pregnancy or lactation women or women may be positive for pregnancy before the first medication.
* Patient has fertility but not willing to take contraceptive measures or whose sexual partners are unwilling to take contraceptive measures.
* Researcher believes the patient's condition is not suitable for the clinical study.
* Researcher judged the patient's lack of compliance with the study.
* Known severe hypersensitivity to gefitinib or any of the excipients of this product.